Epidemiology

You have full text access to this OnlineOpen article

Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: A population-based case-control study

  1. Eero Pukkala1,†,*,
  2. Pentti Kyyrönen1,
  3. Risto Sankila1,
  4. Kaija Holli2

Article first published online: 24 MAY 2002

DOI: 10.1002/ijc.10454

Issue

International Journal of Cancer

International Journal of Cancer

Volume 100, Issue 3, pages 337–341, 20 July 2002

Additional Information

How to Cite

Pukkala, E., Kyyrönen, P., Sankila, R. and Holli, K. (2002), Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: A population-based case-control study. Int. J. Cancer, 100: 337–341. doi: 10.1002/ijc.10454

Author Information

  1. 1

    Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland

  2. 2

    Tampere University Hospital, University of Tampere, Tampere, Finland

  1. †

    Fax: +358-9-135-5378

*Finnish Cancer Registry, Liisankatu 21 B, 00170 Helsinki, Finland

Publication History

  1. Issue published online: 27 JUN 2002
  2. Article first published online: 24 MAY 2002
  3. Manuscript Accepted: 26 MAR 2002
  4. Manuscript Revised: 25 MAR 2002
  5. Manuscript Received: 26 NOV 2001

Funded by

  • Orion Pharma

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (76K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Marisa R. Nucci, Bradley J. Quade, Diagnostic Gynecologic and Obstetric Pathology, 2011,

    CrossRef

  2. 2
    Henry T. Lynch, Murray Joseph Casey, Carrie L. Snyder, Chhanda Bewtra, Jane F. Lynch, Matthew Butts, Andrew K. Godwin, Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management, Molecular Oncology, 2009, 3, 2, 97

    CrossRef

  3. 3
    Lorenzo Gianni, Shari Gelber, Alberto Ravaioli, Karen N. Price, Ilaria Panzini, Manuela Fantini, Monica Castiglione-Gertsch, Olivia Pagani, Edda Simoncini, Richard D. Gelber, Alan S. Coates, Aron Goldhirsch, Second non-breast primary cancer following adjuvant therapy for early breast cancer: A report from the International Breast Cancer Study Group, European Journal of Cancer, 2009, 45, 4, 561

    CrossRef

  4. 4
    Ayfer Yurt, Fazilet Zumrut B. Muftuler, Perihan Unak, Seniha Yolcular, Cigdem Acar, Huseyin Enginar, Synthesis of a Novel Antiestrogen Radioligand (99mTc-TOR-DTPA), Cancer Biotherapy & Radiopharmaceuticals, 2009, 24, 6, 707

    CrossRef

  5. 5
    Michele Barone, Sabina Tanzi, Katia Lofano, Maria Principia Scavo, Raffaella Guido, Lucia Demarinis, Maria Beatrice Principi, Antongiulio Bucci, Alfredo Di Leo, Estrogens, phytoestrogens and colorectal neoproliferative lesions, Genes & Nutrition, 2008, 3, 1, 7

    CrossRef

  6. 6
    S.-M. SHEEN-CHEN, H.-L. ENG, Development of malignant lymphoma subsequent to breast cancer, European Journal of Cancer Care, 2007, 16, 4
    Direct Link:
  7. 7
    Mandana Saadat, Pauline T. Truong, Hosam A. Kader, Caroline H. Speers, Eric Berthelet, Elissa McMurtrie, Ivo A. Olivotto, Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer , Cancer, 2007, 110, 1
    Direct Link:
  8. 8
    Wilhelmina E. Hoogendoorn, Harry Hollema, Hester H. Boven, Elisabeth Bergman, Geri Leeuw-Mantel, Inge Platteel, Renske Fles, Petra M. Nederlof, Marian J. E. Mourits, Flora E. Leeuwen, Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer, Breast Cancer Research and Treatment, 2007, 112, 1, 99

    CrossRef

  9. 9
    Heon-Kyun Ha, Wonshik Han, Eunyoung Ko, So Young Kang, Jong Won Lee, Jihyoung Cho, So-Youn Jung, Eun-Kyu Kim, Seung Keun Oh, Yeo-Kyu Youn, Dong-Young Noh, Toremifene as an Adjuvant Hormone Therapy for Estrogen Receptor Positive early Breast Cancer: Therapeutic Efficacy and Effect on Endometrium, Journal of Breast Cancer, 2007, 10, 4, 258

    CrossRef

  10. 10
    S Oksa, T Luukkaala, J Mäenpää, Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study, BJOG: An International Journal of Obstetrics & Gynaecology, 2006, 113, 6
    Direct Link:
  11. 11
    Harold A. Harvey, Morihiko Kimura, Alajos Hajba, Toremifene: An evaluation of its safety profile, The Breast, 2006, 15, 2, 142

    CrossRef

  12. 12
    M V Blagosklonny, Carcinogenesis, cancer therapy and chemoprevention, Cell Death and Differentiation, 2005, 12, 6, 592

    CrossRef

  13. 13
    Mika Wall�n, Eija Tom�s, Tapio Visakorpi, Kaija Holli, Johanna M�enp��, Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene, Cancer Chemotherapy and Pharmacology, 2004, 55, 4, 343

    CrossRef

  14. 14
    L. Broxmeyer, Is cancer just an incurable infectious disease?, Medical Hypotheses, 2004, 63, 6, 986

    CrossRef

  15. 15
    Murray Joseph Casey, Chhanda Bewtra, Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations, Familial Cancer, 2004, 3, 3-4, 265

    CrossRef

  16. 16
    Hanna Mäenpää, Pirjo Saransaari, Hanna Tähti, Kinetics of Inhibition of Glutamate Uptake by Antioestrogens, Pharmacology & Toxicology, 2003, 93, 4
    Direct Link:
  17. 17
    MICHAEL W. DRAPER, WILLIAM W. CHIN, Molecular and Clinical Evidence for the Unique Nature of Individual Selective Estrogen Receptor Modulators, Clinical Obstetrics and Gynecology, 2003, 46, 2, 265

    CrossRef

  18. 18
    D Vinatier, G Orazi, Peut-on prévenir chimiquement le cancer du sein en 2003 ?, Gynécologie Obstétrique & Fertilité, 2003, 31, 4, 327

    CrossRef

  19. 19
    Andreana L. Ososki, Edward J. Kennelly, Phytoestrogens: a review of the present state of research, Phytotherapy Research, 2003, 17, 8
    Direct Link:
  20. 20
    Karen Brown, Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen, Expert Opinion on Drug Safety, 2002, 1, 3, 253

    CrossRef

View Full Article (HTML) Get PDF (76K)